THE CONSTANT search for new synthetic mydriatic and cycloplegic drugs as substitutes for homatropine and atropine continues to stimulate the investigator. Most recently, cyclopentylate (Cyclogyl)1 and its allied chemicals* have met with some degree of success as short-acting cycloplegic replacements for homatropine.
Other similar-acting agents,5 whose initial effectiveness proved illusory, have, however, attained limited, though valuable, purposes in the ophthalmological armamentarium. Several such drugs are hydroxyamphetamine (Paredrine), phenylephrine (Neo-Synephrine), eucatropine (Euphthalmine), and Dibutoline.6
There is no adequate long-acting synthetic cycloplegic substitute for atropine. Only BL 1397 (β-β-diphenyl-γ-dimethylaminovaleramide) approaches the efficacy of atropine in its autonomic ganglion-blocking action and its cycloplegic-mydriatic effect. However, it has not been made available.
Oxyphenonium (Antrenyl), as a potential substitute for atropine, came to our attention during the clinical study of its systemic administration, because of its side-reactions—dryness of the mouth and pupillary dilation. The prolonged cycloplegic and mydriatic action of this
ABRAHAMSON IA, HURWITZ P. OXYPHENONIUM (ANTRENYL), A SUBSTITUTE FOR ATROPINE: A Clinical Study. AMA Arch Ophthalmol. 1954;52(4):519–523. doi:10.1001/archopht.1954.00920050521003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: